The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not ...
(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.
The eye drops were initially approved for treating presbyopia in adults, but this approval was suspended on September 10, by the Central Drugs Standard Control Organization (CDSCO) following what ...
LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate sa ...